On July 3, 2026, researchers led by Dr. Wang Yu from the Shenzhen Institute of Advanced Technology developed a novel CRISPR editing system that allows for controlled genome editing in living tissues. Published in Science Translational Medicine, this study presents innovative small-molecule switches that regulate CRISPR activity, enabling precise editing on demand.
Innovative CRISPR Editing with Small-Molecule Control
The dual systems, named PRINCE and Little Prince, utilize small-molecule drug inducers to switch CRISPR activity on and off. Unlike traditional methods that rely on passive control, these systems maintain silent states until activated, allowing for enhanced precision in genome editing. Dr. Wang stated, "Natural decay is not the same as active control. Our goal is to make genome editing not only efficient, but also controllable in time." This approach addresses the limitations of existing therapeutic CRISPR strategies that often suffer from unintended off-target effects.
PRINCE coordinates two regulatory layers, controlling the nuclease protein and guide RNA expression through small-molecule-responsive systems. This design minimizes background editing while ensuring efficient activation when needed. In human cell cultures, PRINCE demonstrated robust control, activating editing after just a 24-hour exposure to drug inducers, while uninduced cells exhibited minimal background activity.
Compact Delivery System for In Vivo Applications
To enhance delivery in vivo, the researchers developed Little Prince, a compact version of the system that can fit within a single adeno-associated virus vector. This innovation aims to facilitate targeted genome editing, particularly for conditions like hypercholesterolemia and age-related macular degeneration. In preclinical studies, Little Prince effectively targeted human PCSK9 in the liver, significantly reducing serum cholesterol levels by approximately 50%.
